Q3 2025 saw strong revenue and EBITDA growth, led by U.S. expansion and Cystatin C adoption. Gross margin recovered, and R&D advanced NT-proBNP and other projects. Cautious outlook for China, but U.S. momentum expected to continue.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.